Rolipram reduces the inotropic tachyphylaxis of glucagon in rat ventricular myocardium

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 370, Issue 4, 2004, Pages 324-329

  Juan Fita, Maria Jesús ^a   Vargas, Maria Luisa ^a   Kaumann, Alberto J ^b   Cascales, Jesus Hernández ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

cAMP; Contractility; Dobutamine; Glucagon; Phosphodiesterase 4; Rat ventricle; Rolipram

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; CALCIUM ION; CYCLIC AMP; DOBUTAMINE; GLUCAGON; GLUCAGON RECEPTOR; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM;

ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE; HYDROLYSIS; INOTROPISM; MALE; NONHUMAN; RAT; TACHYPHYLAXIS;

ANIMALS; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON; HEART VENTRICLES; MALE; MYOCARDIAL CONTRACTION; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM; TACHYPHYLAXIS;

EID: 11244320313     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-004-0978-6     Document Type: Article

References (20)

1. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75:725-748
2. Cleary L, Buber R, Docherty JR (2002) Effects of amphetamine derivatives and cathinone on noradrenaline-evoked contractions of rat right ventricle. Eur J Pharmacol 451:303-308
3. Conti M, Jin SL (1999) The molecular biology of cyclic nucleotide phosphodiesterases. Adv Nucleic Acid Res 63:1-38
4. Ewy GA, Plachetka JR (1992) Dopamine and dobutamine: pharmacology and use in advanced heart failure. In: Ewy GA, Bressler R (eds) Cardiovascular drugs and the management of heart disease. Raven, New York, pp 65-82
5. Farah A, Tuttle R (1960) Studies on the pharmacology of glucagon. J Exp Pharmacol Ther 129:49-55
6. Hernandez J, Juan-Fita MI, Vargas MJ (2004) Milrinone enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium: comparison with other phosphodiesterase inhibitors. Fundam Clin Pharmacol 18 [Suppl 1]:35
7. Juan-Fita MJ, Vargas ML, Hernández J (2003) Comparative actions of diazepam and other phosphodiesterase inhibitors on the effects of noradrenaline in rat myocardium. Pharmacol Toxicol 93:23-28
8. Katano Y, Endoh M (1992) Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone and isobutylmethylxantine. J Cardiovasc Pharmacol 20:715-722
9. Luttrell LM, Lefkowitz RJ (2002) The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115:455-465
10. MacKenzie SJ, Baillie GS, McPhee I, MacKenzie C, Seamons R, McSorley T, Millen J, Beard MB, van Heeke G, Houslay MD (2002) Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in upstream conserved region 1 (UCR1). Br J Pharmacol 136:421-433
11. MacLeod KM, Rodgers RL, McNeill JH (1981) Characterization of glucagon-induced changes in rate, contractility and cyclic AMP levels in isolated cardiac preparation of the rat and guinea pig. J Pharmacol Exp Ther 217:798-804
12. Marcus ML, Skelton CL, Prindle KH, Epstein SE (1971) Potentiation of the inotropic effects of glucagon by theophylline. J Pharmacol Exp Ther 179:331-337
13. 2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. Nature 345:158-161
14. 1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol 111:539-545
15. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker H, Lohse MJ, Pozzan T, Housley MD, Zaccolo M (2004) Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 95:67-75
16. Nicholson CD, Challiss RAJ, Shahid M (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12:19-27
17. 2-adrenergic receptors by β-arrestins. Science 298:834-836
18. Verde I, Vandecasteele G, Lezoualch F, Fischmeister R (1999) Characterization of the cyclic nucleotide phosphodiesterase subtypes in the regulation of the L-type calcium current in rat ventricular myocytes. Br J Pharmacol 127:65-74
19. White CM (1999) A review of potential cardiovascular uses of intravenous glucagon administration. J Clin Pharmacol 39:442-447
20. Yao LF, Macleod KM, McNeill JH (1982) Glucagon induced desensitization: correlation between cyclic AMP levels and contractile force. Eur J Pharmacol 79:147-150